Novo Nordisk CEO Lars Fruergaard Jorgensen will testify Tuesday before a Senate panel looking into the drug maker's pricing of weight-loss drugs Wegovy and Ozempic.

Novo Nordisk CEO Lars Fruergaard Jørgensen faces a Senate hearing led by Bernie Sanders over the high cost of Ozempic and Wegovy, as U.S. lawmakers push for drug price reductions.

As the Senate Committee on Health, Education, Labor and Pensions (HELP) gears up for a hearing tomorrow titled “Why Is Novo Nordisk Charging Americans with Diabetes and Obesity Outrageously High Prices for Ozempic and Wegovy?

In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months. Amycretin targets GLP-1 receptors and a second hormone called amylin. Amylin appears to act in the brain,

Novo Nordisk's chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the high price of blockbuster diabetes and weight loss drugs, as Ozempic falls into the scope of U.

Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to its trial results, it has some pretty freaky side effects. As Fierce Biotech reports,

A Senate Committee on Health, Education, Labor and Pension hearing scheduled for Tuesday has all the makings of a showdown as Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen is set to be the sole witness to testify about the drugmaker's prices for the diabetes and weight loss drugs Ozempic and Wegovy.